Paraneoplastic syndrome
Reading File
Finding Sources
Searching PubMed
"paraneoplastic syndrome" AND diagnosis
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
I now have comprehensive, high-quality content from Harrison's 22E and Goldman-Cecil to write a detailed answer. Let me compile the full response.
Paraneoplastic Syndromes
Definition
Paraneoplasia ("alongside cancer") refers to a cancer's remote effects that cannot be attributed to direct invasion, metastasis, or common complications such as infection, coagulopathy, or treatment toxicity. These syndromes affect up to 15% of cancer patients (falling to a few percent when cachexia is excluded). Importantly, up to two-thirds arise before the underlying malignancy is diagnosed, making their recognition clinically critical.
- Harrison's Principles of Internal Medicine 22E, Ch. 99
- Goldman-Cecil Medicine, Ch. 164
Pathogenesis
Paraneoplastic syndromes arise by several mechanisms:
1. Ectopic Hormone / Substance Production
Tumors secrete biologically active substances - hormones, hormone-like peptides, cytokines, growth factors, or enzymes - that act at distant sites. Examples include ACTH secretion by SCLC causing Cushing syndrome, and PTHrP secretion causing hypercalcemia.
2. Autoimmune / Antibody-Mediated (Neurologic PNDs)
Tumors ectopically express neural proteins, triggering immune responses. Two major mechanisms:
Antibodies against intracellular antigens (e.g., anti-Hu, anti-Yo):
- Cytotoxic T-cells are the main effectors
- Antibodies cannot reach intracellular targets
- Results in irreversible neuronal loss
- Poor response to immunotherapy
Antibodies against cell-surface / synaptic antigens (e.g., anti-NMDAR, anti-LGI1, anti-CASPR2):
- Antibodies directly bind and alter receptor/channel function
- Neuronal loss is less severe
- Better response to immunotherapy and tumor treatment
Classification by System
I. Neurologic Paraneoplastic Disorders (PNDs)
Clinically disabling PNDs occur in 0.5-1% of all cancer patients, but in 2-3% with neuroblastoma or SCLC and 30-50% with thymoma. In 60% of patients, neurologic symptoms precede the cancer diagnosis.
Only 60-70% of CNS PNDs and <20% of peripheral PNDs have detectable neuronal antibodies.
| Syndrome | Key Features | Associated Tumor | Antibody |
|---|---|---|---|
| Lambert-Eaton Myasthenic Syndrome (LEMS) | Proximal lower limb weakness, strength improves with sustained contraction; autonomic features | SCLC (>50%) | Anti-VGCC, anti-SOX1 |
| Paraneoplastic Encephalomyelitis / Subacute Sensory Neuropathy | Asymmetric numbness, burning paresthesias, sensory ataxia, loss of proprioception/vibration | SCLC | Anti-Hu (ANNA-1) |
| Paraneoplastic Cerebellar Degeneration (PCD) | Abrupt onset dysarthria, ataxia, oculomotor dysfunction; Purkinje cell loss; cerebellar atrophy on MRI | Breast, ovarian, SCLC, Hodgkin lymphoma | Anti-Yo (PCA-1), anti-Hu, anti-Ri, anti-Tr |
| Limbic Encephalitis | Subacute amnesia, affective disorders, seizures; mesial temporal FLAIR signal on MRI | SCLC, testicular (NMDAR), thymoma | Anti-Hu, anti-Ma2, anti-LGI1, anti-CASPR2, anti-AMPAR |
| Stiff-Person Syndrome | Progressive muscle stiffness, rigidity, painful spasms | Breast cancer | Anti-GAD65, anti-amphiphysin |
| Paraneoplastic Opsoclonus-Myoclonus | Chaotic multidirectional eye movements + myoclonus | Breast cancer (adults), neuroblastoma (children) | Anti-Ri |
| Paraneoplastic Neuropathy | Sensorimotor neuropathy, demyelinating variants | Multiple | Anti-CRMP5 (CV2), anti-Hu |
| Dermatomyositis/Polymyositis | Proximal muscle weakness, rash (DM) | Lung, ovarian, colorectal, bladder | Anti-Jo-1, anti-Mi-2 |
II. Endocrine / Metabolic Paraneoplastic Syndromes
| Syndrome | Mechanism | Associated Tumor |
|---|---|---|
| Humoral hypercalcemia of malignancy | PTHrP secretion | Squamous cell lung, breast, renal cell, bladder |
| SIADH / Hyponatremia | Ectopic ADH | SCLC, CNS tumors, head and neck cancers |
| Cushing Syndrome | Ectopic ACTH | SCLC, pancreatic NET, bronchial carcinoid, medullary thyroid cancer |
| Hypoglycemia | Ectopic IGF-2 | Mesenchymal tumors, hepatocellular carcinoma |
| Acromegaly | Ectopic GHRH | Pancreatic islet, carcinoid tumors |
| Carcinoid Syndrome | Serotonin, bradykinin | GI carcinoids with liver mets, bronchial carcinoid |
| VIPoma (Watery diarrhea) | Ectopic VIP | Pancreatic islet cell tumors |
III. Hematologic Paraneoplastic Syndromes
- Erythrocytosis - ectopic EPO from renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma
- Granulocytosis / Leukocytosis - ectopic G-CSF, GM-CSF (lung, bladder, GI tumors)
- Thrombocytosis - tumor-secreted IL-6, thrombopoietin (various solid tumors)
- Autoimmune hemolytic anemia - lymphomas, CLL
- DIC - mucin-secreting adenocarcinomas (pancreatic, gastric), promyelocytic leukemia
- Trousseau syndrome - migratory thrombophlebitis (pancreatic, lung, GI cancers)
IV. Dermatologic Paraneoplastic Syndromes
| Skin Finding | Associated Malignancy |
|---|---|
| Acanthosis nigricans | GI adenocarcinoma (especially gastric) |
| Dermatomyositis | Ovarian, lung, GI cancers |
| Bazex syndrome (acrokeratosis paraneoplastica) | Head and neck squamous cell carcinoma |
| Erythema gyratum repens | Lung, breast, esophageal cancers |
| Necrolytic migratory erythema | Glucagonoma |
| Sweet syndrome | AML, myelodysplastic syndrome |
| Paraneoplastic pemphigus | NHL, CLL, thymoma, Castleman disease |
| Leser-Trelat sign (sudden eruption of seborrheic keratoses) | GI adenocarcinomas |
V. Rheumatologic / Musculoskeletal Paraneoplastic Syndromes
- Hypertrophic osteoarthropathy (periosteal new bone formation, clubbing) - lung cancer, pleural mesothelioma
- Palmar fasciitis and polyarthritis syndrome - ovarian cancer
- Polymyalgia-like syndrome - various solid tumors
- Carcinomatous polyarthritis - large joint oligoarthritis/polyarthritis preceding cancer diagnosis
VI. Renal and Hepatic Paraneoplastic Syndromes
- Nephrotic syndrome (membranous nephropathy) - colon, lung, gastric cancers; Hodgkin lymphoma
- Minimal change disease - Hodgkin lymphoma
- Stauffer syndrome (non-metastatic hepatic dysfunction) - renal cell carcinoma
Key Antibodies in Neurologic PNDs
"High-risk" antibodies (strongly predict cancer - usually intracellular targets, T-cell mediated, poor prognosis):
- Anti-Hu (ANNA-1) - SCLC; encephalomyelitis, sensory neuropathy
- Anti-Yo (PCA-1) - breast, ovarian; cerebellar degeneration
- Anti-Ri (ANNA-2) - breast; opsoclonus-myoclonus
- Anti-Ma2 - testicular; limbic/brainstem encephalitis
- Anti-CV2 (CRMP5) - SCLC; encephalomyelitis, neuropathy
- Anti-amphiphysin - SCLC, breast; stiff-person syndrome
"Lower-risk" or surface-antigen antibodies (less often paraneoplastic, better prognosis):
- Anti-NMDAR - ovarian teratoma (especially young women); encephalitis
- Anti-LGI1 - thymoma, SCLC; limbic encephalitis, faciobrachial dystonic seizures
- Anti-CASPR2 - thymoma; Morvan syndrome, limbic encephalitis
- Anti-GABA-B - SCLC; limbic encephalitis with prominent seizures
- Anti-AMPAR - thymoma, SCLC, breast; limbic encephalitis
- Anti-VGCC - SCLC; LEMS, cerebellar degeneration
Diagnosis
A stepwise approach (Goldman-Cecil Table 164-6):
- Characterize the abnormality and obtain appropriate labs/biopsy
- Exclude common causes (metastatic disease, infection, medication toxicity, metabolic derangement)
- Consider paraneoplastic syndrome if no obvious etiology
- Screen for malignancy: physical exam (including breast, gynecologic, prostate), CBC, CMP, urinalysis, CXR, mammogram; CT abdomen/pelvis or whole-body PET-CT for suspicious findings
- Order antibody panel (for neurologic syndromes); skin biopsy as indicated
- For germ cell tumors: scrotal/transvaginal ultrasound + pelvic MRI (PET may miss)
- If PND antibodies negative: diagnosis relies on demonstrating cancer and excluding other disorders
- CSF (in PNDs of CNS): mild pleocytosis (<200 mononuclear cells), elevated protein, variable oligoclonal bands
Treatment
Core principle: Effective treatment of the underlying tumor is the most important step and often produces improvement or resolution of the syndrome. Return of systemic symptoms may herald cancer recurrence.
Neurologic PNDs:
- Intracellular antigen-associated (Hu, Yo, etc.): Aggressive tumor treatment is priority. Limited benefit from immunotherapy. Many have irreversible deficits due to T-cell-mediated neuronal loss.
- Cell-surface antigen-associated (NMDAR, LGI1, etc.): Respond better to immunotherapy. Standard escalation: glucocorticoids + IVIg + plasma exchange first line; rituximab or cyclophosphamide second line. Tumor treatment (if applicable) is also key.
Endocrine/metabolic:
- Treat underlying malignancy
- Specific management: bisphosphonates/denosumab/cinacalcet for hypercalcemia; demeclocycline/tolvaptan/fluid restriction for SIADH; metyrapone/ketoconazole/osilodrostat for ectopic Cushing
LEMS: Pyridostigmine + 3,4-diaminopyridine (3,4-DAP) for symptomatic relief; tumor treatment
Key Clinical Pearls
- LEMS strength improves with repeated activity (opposite of myasthenia gravis - EMG shows incremental response at >10 Hz stimulation)
- Cerebellar degeneration from PND is often abrupt and severe, unlike many other cerebellar disorders
- Anti-NMDAR encephalitis classically affects young women with ovarian teratoma and follows a stereotyped course: psychiatric symptoms → seizures → movement disorders → decreased consciousness → autonomic instability
- The syndrome course parallels the tumor - effective treatment leads to improvement; recurrence signals tumor relapse
- Periodic tumor surveillance is needed even after negative initial workup (e.g., repeat screening q6 months x 3 years for LEMS given high SCLC risk)
Sources:
- Harrison's Principles of Internal Medicine, 22E (2025) - Chapters 99 (Paraneoplastic Neurologic Syndromes) and 98 (Oncologic Emergencies)
- Goldman-Cecil Medicine - Chapter 164 (Approach to the Patient with Cancer)
- Recent PubMed: Oral manifestations in paraneoplastic syndromes - systematic review and meta-analysis (PMID 39415566, Oral Dis 2025); Nephrotic syndrome with solid malignancies - systematic review (PMID 38965515, BMC Nephrol 2024)
Create a diagnostic flowchart for suspected paraneoplastic syndrome
Asking for Preferences
Reading File
Running Command
Writing File
Running Command
Running Command
Running Command
Running Command
Running Command
Reading File
Writing File
Running Command
Running Command
Reading File
Running Command
Editing File
Editing File
Running Command
Reading File
The flowchart looks clean and well-organized. The layout flows clearly from top to bottom, the two columns are well separated, all major content is readable, and the monitoring oval terminates the flow at the bottom. The file is ready.
Your diagnostic flowchart PDF is ready for download:
paraneoplastic diagnostic flowchart
PDF Document · PDF
What's included in the flowchart:
The chart is A3 landscape and walks through 6 structured steps:
- Start - Patient with unexplained symptoms
- Step 1 - Initial assessment (history, labs, imaging)
- Step 2 - Exclude common causes (metastasis, infection, drug toxicity, metabolic)
- Decision diamond - Cause identified? YES (treat) / NO (suspect PNS)
- Step 3 - Classify dominant syndrome system → splits into two parallel columns:
- Left (Neurologic): Full workup (MRI, CSF, antibody panel), "Antibody Positive?" decision, confirmed vs probable PNS, neurologic treatment protocol
- Right (Non-neurologic): Targeted labs per syndrome, "Tumour Identified?" decision, tumour treatment vs symptomatic Rx, non-neurologic treatment protocol
- Central reference panels - Key antibodies (high-risk vs surface-antigen) and non-neurologic PNS examples
- Monitoring oval at the bottom - reassess every 3-6 months; PNS recurrence signals tumour relapse
All content is sourced from Harrison's Principles of Internal Medicine 22E (2025) and Goldman-Cecil Medicine.
This is a shared conversation. Sign in to Orris to start your own chat.